A high throughput assay to measure Type VII secretion in *Staphylococcus aureus*

Yaping Yang[1], Felicity Alcock[1], Holger Kneuper[2] and Tracy Palmer[1]

[1]Newcastle University Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK.

[2]Present address: Folium Science, Old Market, Midland Road, Bristol BS2 0JZ

To whom correspondence should be addressed.

e-mail: tracy.palmer@newcastle.ac.uk

Tel +44 191 208 3219

Keywords: Type VII secretion system, *Staphylococcus aureus*, protein secretion, bioluminescence, NanoLuc, NanoBit

Abstract

Successful colonisation by the opportunistic pathogen *Staphylococcus aureus* depends on its ability to interact with other microorganisms. *S. aureus* strains harbour a T7b-subtype type VII secretion system (T7SSb), a protein secretion system found in a wide variety of Firmicutes which functions in bacterial antagonism and virulence. Traditional assays for monitoring protein secretion by the T7SSb rely on concentrating cell culture supernatants for immunoblot analysis, a procedure which is time consuming, low throughput, non-quantitative and has low sensitivity. To overcome some of these disadvantages we have utilised NanoLuc Binary Technology to develop a simple assay to monitor protein secretion via detection of bioluminescence in 384-well plates. High-throughput analysis of secretion in replicate cultures reveals overlapping distributions for T7$^+$ and T7$^-$ populations highlighting a significant limitation of lower-throughput methods. We also demonstrate the utility of the NanoLuc assay in comparing T7-dependent protein secretion across different strains and find differences in the temperature dependence of T7 secretion across *S. aureus* isolates.

Introduction

The opportunistic pathogen *Staphylococcus aureus* is a major cause of both nosocomial and community-acquired infections. It is a frequent coloniser of animals and humans, and infections can result in a range of life-threatening diseases such as pneumonia, endocarditis and sepsis. It is notorious for developing resistance to front line antimicrobials, with methicillin resistance now widespread and vancomycin resistance also increasing (1, 2). Like many Gram-positive bacteria, *S. aureus* carries a specialised protein secretion machinery called the Type VII secretion system (T7SS), which it utilises to secrete antibacterial toxins targeting competitor bacteria (3). T7SS-mediated antagonism is likely to be important for colonisation (4), and the *S. aureus* T7SS has been shown to be required for virulence in mouse infection models (5-9). There are two distinct T7SS subtypes, T7SSa and T7SSb, with the latter being widely distributed among firmicutes. The T7SSb has been studied to date in species of *Streptococcus*, *Staphylococcus*, *Bacillus* and *Enterococcus* (7, 10-12), however in many cases functional and mechanistic studies are hindered by low secretion activity in laboratory conditions*.*

The *S. aureus* T7SSb is encoded on the core genome at the *ess* locus, and four variant locus types have been identified, *essC-1 – essC-4* (13). The genes at the 5' end of the *ess* locus are highly conserved and encode core components of the secretion machinery, while the 3' end codes for different complements of variant-specific substrate and accessory genes. The primary component of the T7SSb transmembrane channel is the ATPase EssC, inferred from homology to the EccC component of the mycobacterial T7SSa machinery whose structure has been solved by cryo-electron microscopy (14, 15). EssC has a conserved N-terminus, two transmembrane domains which form the secretion channel, and four C-terminal ATPase domains, the latter two of which are variant-specific and provide substrate specificity (16). Two types of T7SSb-secreted substrates have been identified to date: Small WXG100 family, or WXG100-like, proteins such as EsxA, and larger LXG domain-containing toxins such as TelB and TspA (6, 10, 17, 18). EsxA is itself a highly conserved core functional component of the T7SS machinery (6, 7).

Secretion of endogenous *S. aureus* WXG100-family proteins has previously been observed by
centrifuging exponential phase cultures, concentrating filtered supernatants (usually by
precipitation with trichloroacetic acid) and immunoblotting (6, 7, 19, 20). For LXG proteins a
similar protocol has been followed but generally with an epitope-tagged substrate
overproduced from an inducible plasmid (3, 18, 21). These assays are laborious, time
consuming and lack sensitivity – millilitres of culture supernatant are often required, and
detection depends on the availability of good quality antibodies. The immunoblot data are
poorly reproducible and are difficult to quantify, and the lack of cleavable signal peptides on
T7SSb substrates means there is no size difference between the exported and cytosolic forms
making cellular lysis a confounding issue. T7 activity across different *S. aureus* isolates and
growth conditions has previously been assessed by monitoring secretion of EsxA by
immunoblot (6, 7, 19, 20). While some strains clearly have a higher basal T7SS activity than
others in laboratory conditions, low activity is a problem in all strains and differences are
difficult to quantify given the shortcomings of current assay methods.

Here we have utilised NanoLuc binary technology (abbreviated to NanoBit) to develop a novel
assay for T7SS secretion in *S. aureus* which overcomes many of the limitations of immunoblot-
based assays. NanoLuc is an engineered variant of a deep-sea shrimp luciferase protein. It is
relatively small (19 kDa) and has superior biophysical characteristics compared to other
luciferases (22). NanoBit is a complementation reporter system which has previously been
used to investigate protein secretion via the Sec and Tat translocons in *E. coli* (23-25). Two
separate NanoLuc subunits (11S, a 156 amino acid 'large' subunit and pep86, an 11 amino
acid 'small' subunit) combine with to generate the functional enzyme, which luminesces with
high intensity at 460 nm in the presence of the substrate furimazine and molecular oxygen
(22). We therefore anticipated that secretion would be straightforward to monitor by
expressing a pep86-tagged substrate within *S. aureus* cells, and provision of purified 11S and
furimazine externally (Fig. 1A). We also reasoned that the short pep86 tag is unlikely to
interfere with substrate translocation as other short peptide tags are tolerated on T7SSb
substrates (e.g. (3, 18)). We show that the NanoLuc assay can be used to monitor and quantify
T7-dependent secretion of the model substrate EsxA. We use this to develop a high
throughput NanoLuc secretion assay to assess the distribution of EsxA secretion levels within
a clonal population and compare EsxA secretion levels across different *S. aureus* isolates.

Results

***A NanoLuc assay for measuring Type VII-dependent secretion in** Staphylococcus aureus*

We selected the conserved, ubiquitous T7-secreted protein EsxA as our model substrate. EsxA

is produced at significantly higher copy number than other T7 components (7) and can be

detected by Western blot in culture supernatants of the *essC-1* strain COL relatively reliably,

allowing us to correlate the NanoLuc assay with data from traditional immunoblots. We first

constructed plasmid pRab11-*esxAp86* which permits inducible overproduction of EsxA with

the NanoBit small subunit, pep86, fused to its C-terminus. This plasmid, or an empty vector

control was transferred into wild-type and Δ*essC* variants of the *S. aureus essC-1* strain COL,

expression of plasmid-encoded *esxAp86* was induced and cells were grown at 37°C to mid

logarithmic phase. At this point, samples of whole cells, culture supernatant or lysostaphin-

lysed cells were prepared, serially diluted and incubated with the NanoBit large subunit, 11S

in 96 well plates. Following addition of the NanoLuc substrate furimazine, OD_{600nm} and

luminescence were measured (Fig. 1B), and the whole cell and supernatant samples were also

analysed by immunoblot (Fig. 1C).

Fig. 1B shows that luminescence can be detected in all samples except those derived from

cells carrying the empty vector, signifying an EsxA-pep86–specific luminescence signal. Similar

luminescence readings were obtained for whole cell culture or supernatant samples,

demonstrating that external pep86 can be measured without centrifugal separation of cells

from culture supernatants (Fig. 1B). Deletion of *essC* drastically reduces the level of

extracellular EsxA-pep86, and we presume that the low level of extracellular EsxA-pep86

detected from the mutant strain results from leakage or cell lysis. Two-fold dilution of the

cytoplasmic fractions indicate that EsxA-pep86 is present at similar levels in both strains.

When fractions of the same cultures were analysed by immunoblot, a single band at ~11 kDa

was detected with antibodies against EsxA in all samples, even those that did not harbour

plasmid-encoded *esxAp86* (Fig. 1C). Since all strains have chromosomally encoded *esxA*, we

infer that this band corresponds to endogenous EsxA (which has a mass of 11 kDa), and that

the pep86 fusion (which increases the mass to 12.3 kDa) inhibits detection by our EsxA

antibodies (see also Fig. 2C where chromosomal tagging of *esxA* with pep86 inhibits antibody

detection).

For comparison with a non-secreted control protein, we constructed a plasmid for production

of the cytoplasmic protein TrxA with an N-terminal pep86 fusion (pRab11-pep86-TrxA) and

assayed this in a similar way. Luminescence readings showed that while the cytoplasmic

control pep86-TrxA was produced, barely any protein was detected outside the cells (Fig. 1D).

Immunoblots confirmed the cytoplasmic localisation of TrxA and showed that EsxA was

secreted normally in these strains, although similar to EsxA-pep86, the pep86-TrxA fusion did

not appear to be detected by our TrxA antibodies (Fig. 1E). While cytoplasmic readings for

TrxA-pep86 in the Δ*essC* strain were comparable to those for EsxA-pep86 (compare Fig. 1B

and 1D 'cytoplasmic' blue bars), the luminescence signal corresponding to extracellular

protein in the Δ*essC* strain was much higher for EsxA-pep86 (compare Fig. 1B and 1D

'supernatant' blue bars). This might imply that overproduction of EsxA (but not TrxA) in cells

lacking EssC causes some cytoplasmic leakage – the definitive cause requires further

investigation, although it should be noted that EsxA has been implicated in membrane

destabilisation (26). In summary, Figure 1 demonstrates that luminescence readings correlate

with T7-dependent secretion of EsxA-pep86, and that extracellular EsxA-pep86 can be

measured in unprocessed whole cell cultures.

High throughput analysis of EsxA secretion

Having established a simple, quantitative NanoLuc assay we next sought to convert it to high

throughput format to improve quantitation and sensitivity. Traditional blotting-based assays

are not amenable to this format due to both the large culture volumes and laborious sample

processing they require. To ensure our system was as close to native as possible, we

engineered the C-terminal pep86 fusion onto chromosomally-encoded EsxA at the *ess* locus,

avoiding the need for an inducible plasmid.

To assess whether the chromosomally encoded EsxA-pep86 fusion was functional, we

transformed this strain with a plasmid carrying an HA-tagged copy of the T7SS substrate EsaD

alongside its partner proteins EsxB, EsxC, EsxD, EsaE and EsaG (21). Immunoblot analysis of

cell and culture supernatant samples showed that when COL produced EsxA-pep86 as the

sole form of EsxA, secretion of EsaD-HA was similar to that seen for the wild type strain (Fig.

2A). This indicates that the pep86 tag does not detectably impede EsxA activity. However, the

EsxA-pep86 fusion was not detected by our EsxA antibodies, suggesting that the tag masks

the major antigenic epitope of EsxA.

We analysed growth kinetics of the COL$_{esxAp86}$ and COL$_{esxAp86}$ $\Delta essC$ strains in 50 µl culture

volumes in 384-well plate format. The strains showed slow growth kinetics in these

conditions, with cultures reaching stationary phase approximately 48 hours (2880 minutes)

following initial inoculation to an OD$_{600}$ of 0.1 (Fig. 2B). Since the half-life of the NanoLuc

luminescence signal is reported to be approximately 120 minutes (Promega), continuous

monitoring of secreted EsxA-p86 throughout exponential growth was not possible. We

therefore initially chose to monitor secretion during early exponential phase, and to this end

furimazine and 11S were added to initiate luminescence measurement after 360 minutes of

growth (dotted line on Fig. 2B). Luminescence readings of the whole cell culture were

subsequently taken every ten minutes after supplementation. The luminescent signal for the

COL$_{esxAp86}$ culture initially rose, peaking 70 minutes after initiation of luminescence, indicating

that cells were actively secreting protein during this time (Fig. 2C). The subsequent decline of

the luminescence readings is likely due to signal decay, although potentially degradation of

pep86 could also contribute. As seen with the plasmid-based assay, there was some EssC-

independent leakage of EsxA-p86 in the $\Delta essC$ strain but the luminescent signal was much

lower than that of the $essC^+$ strain (Fig. 2C).

To analyse the distribution of secretion activity within a clonal population, a single colony

of each of COL$_{esxAp86}$ and COL$_{esxAp86}$ $\Delta essC$ was used to inoculate overnight cultures, and these

were subsequently used to inoculate 64 x 50 µl cultures in 384 well format. Furimazine and

11S were added to initiate luminescence measurement after 360 minutes of growth as

before, and luminescence was read at a single timepoint of 430 minutes (A$_{600nm}$ = 0.23), which

is where we had observed the greatest difference in luminescence signal between the two

strains in Fig. 2C. These individual data points were used to generate a scatter plot (Fig. 2D).

This analysis reveals a relatively narrow distribution of secretion activity in replicate cultures

of COL$_{esxAp86}$, however the distribution of extracellular EsxA-p86 levels in the control COL$_{esxAp86}$

Δ*essC* strain was quite broad, overlapping the *essC*$^+$ strain and highlighting the requirement

for a high throughput assay. The same analysis was repeated using three independent

overnight cultures of each strain but this did not increase variability (Fig. 2E).

Variable secretion characteristics of different* S. aureus *strains

Direct comparison of T7SS activity across different *S. aureus* strains has been hampered by

low secretion activity (often below the detection limit (7, 20)) and low reproducibility (our

unpublished observations). We used the NanoLuc assay to compare secretion across five

additional *S. aureus* isolates, two of which (like COL) carry the *essC-1* allele (RN6390 and

JP5347), and one representative isolate for each of *essC-2* (10.125.2X)*, essC-3* (MRSA252) and

essC-4 (EMRSA15). Each strain and its isogenic Δ*essC* variant was transformed with pRab11-

esxAp86, and these were cultured in 384-well plates in the presence of anhydrotetracycline

(ATC) to induce expression of plasmid-encoded EsxA-pep86.

Although growth curves revealed different growth kinetics for the six isolates, each Δ*essC*

variant grew similarly to the otherwise isogenic parental strain, allowing for meaningful

comparison of secreted EsxA (Fig S1A). We noted that each of these five additional strains

entered exponential phase earlier than COL, so we adjusted the timing of addition of 11S and

furimazine to these cultures to 230 minutes, measuring luminescence at ten minute intervals

afterwards (Fig. 3, Fig. S1B). Our analysis revealed that EsxA-p86 was secreted at variable

levels in the three *essC-1* isolates and the *essC-2* representative strain 10.1252.X. However,

T7SS-dependent secretion of EsxA was not detected in the *essC-3* and *essC-4* strains,

MRSA252 and EMRSA15 (Fig. 3A, B). We also noted that the level of EssC-independent leakage

of EsxA-p86 varied substantially between strains (Fig. 3A, Fig. S2). Since lysostaphin treatment

of cells for measurement of cytoplasmic EsxA-pep86 is not possible in the 384-well plate

format, we also conducted a NanoLuc assay for each strain in 5 ml cultures to ensure that

EsxA-pep86 was produced in all strains, observing that cytoplasmic EsxA-pep86 was present

in excess over the secreted protein in all cases (Fig. S2). The lack of secreted protein in

MRSA252 and EMRSA15 is therefore not due to a lack of EsxA in the cytosol.

Since no T7SS activity was detected in MRSA252 and EMRSA15 at 37°C we wondered whether

these strains might exhibit a different temperature dependence and so we repeated the

growth curves and NanoLuc secretion assay for these strains, alongside RN6390 as an *essC-1*

control, at 30°C and 34°C (Fig. 4, Fig S3). For EMRSA15, EsxA-p86 was secreted at both 30°C

and 34°C, while for MRSA252 the lower temperatures made negligible difference to secretion

activity. EsxA was secreted to a similar extent in RN6390 at all three temperatures.

Temperature therefore contributes to the regulation of T7 activity in *S. aureus* in a strain-

specific manner.

Discussion

The NanoLuc system is a powerful tool which can be adapted to a wide range of biological

applications and is gaining broad utility in the field of protein translocation (23-25, 27). Here

we develop a novel assay for monitoring protein secretion by the T7SS in *S. aureus*, using the

NanoBit split luciferase system. Luminescence from secreted proteins can be measured

directly in unprocessed cell cultures, enabling the high throughput screening of large numbers

of strains and growth conditions. EssC is the primary component of the T7 machinery, and our

initial experiments in the *essC*-1 strain COL clearly demonstrate that extracellular localisation

of EsxA is dependent on EssC. However, we do observe some extracellularly localised EsxA in

a Δ*essC* strain, and this proportion is higher than would be expected from a 'regular' cell lysis,

as predicted from similar analysis of the control cytoplasmic protein TrxA. Given the central

role of EssC in forming the secretion channel this is unlikely to result from EssC-independent

secretion of EsxA by the T7SS. Instead, we hypothesise that the elevated levels of EsxA-pep86

present in these experiments might destabilise cell membranes causing leakage of some

cytoplasmic components. In support of this hypothesis, EsxA has previously been reported to

have pore-forming activity in synthetic lipid bilayers (26), and this could be particularly

relevant when the EssC component, where EsxA might normally be expected to dock, is

absent*.*

Most studies of the *S. aureus* T7SS have focussed on secretion by *essC-1* type systems, using

a handful of isolates. Further isolates exhibit high genetic diversity at their T7 loci (13), but

experimental investigation of alternate systems has been constrained by their low activity in

laboratory growth conditions, and the lack of a sensitive secretion assay. We have used the

NanoLuc assay to analyse six different strains and find substantial variability in their secretion

efficiencies. A number of pathways have been implicated in transcriptional regulation of the

S. aureus T7SS, including SigB, the SaeRS and ArlRS two-component systems, and the Agr

quorum-sensing system (19, 28-30), however the complex regulatory picture is far from

complete and key questions around how, why and when secretion is activated remain

unanswered. Although no EsxA-pep86 secretion was detected in strain MRSA252, our analysis

was limited to a very early time window at the start of exponential phase; the NanoLuc assay

can be used for future analyses of secretion at different growth stages for this and other

strains. Interestingly, the EMRSA15 T7SS was inactive at 37°C, but was active at the lower

temperatures of 30°C and 34°C suggesting a role for temperature in T7b regulation. This new

assay will facilitate high throughput screening of a range of conditions, paving the way for a

much more detailed analysis of T7 secretion regulation.

Methods

Bacterial strains, plasmids and growth conditions

E. coli was cultured in LB medium (Melford) and *S. aureus* was cultured in tryptic soy broth (TSB; Oxoid) with chloramphenicol (10 µg/ml) where required. *E. coli* strains DH5α and JM110 were used for cloning and preparation of plasmids for electroporation respectively. *S. aureus* strains and plasmids used are listed in Tables S1 and S2, respectively. Chromosomal deletion of *essC* was accomplished by allelic exchange using plasmid pIMAY (31) carrying the flanking regions of the relevant *essC* allele. Insertion of the pep86 tag on the chromosome of COL and COLΔ*essC* used an updated system with plasmid pIMAY-Z (32). pIMAY plasmids were created using standard restriction cloning techniques, and pIMAY-Z-esxAp86 and pRab11-esxAp86 were created using HiFi assembly (NEB). Oligonucleotides are listed in Table S3.

NanoLuc secretion assays

Furimazine was purchased from Promega (Cat. # N1610) and used according to the manufacturer's instructions. The NanoBit large subunit 11S was purified from BL21(DE3) [pBAD-$_{6H}$11S] using the published protocol (24) and was used at a final concentration of 5 µM. For assay of 5 ml cultures, *S. aureus* COL cells were cultured as described above. Once cultures had reached a density of 0.5 (OD$_{600}$), anhydrotetracycline (ATC; 250ng/ml) was added to induce expression of EsxA-pep86. Cells were harvested at a density of 2 (OD$_{600}$) by centrifugation at 16,000 x g, 20°C. Cell pellets were resuspended in TBS + 50µg/ml lysostaphin (Ambi) and incubated for 10 minutes at 37°C. 100µl of each sample was supplemented with 11S and furimazine in a 96-well plate (Greiner, REF655073) with an approximate final well volume of 105µl. Luminescence was read 3 minutes after incubation of the plate at room temperature, with a FLUOstar Omega using a gain value of 3,000. Samples from the same cultures were prepared for immunoblot and analysed with antibodies as previously described (21). For assays in 384-well plates, overnight *S. aureus* cultures were subcultured into fresh TSB at a density of 0.01 (OD$_{600}$) and cultured at 37 °C/34 °C/30 °C with shaking at 200rpm in a 384-well plate (Greiner, REF781098), with a well volume of 50µl. ATC was added after 180 minutes (37°C cultures), 270 minutes (34°C cultures), or 310 minutes (30°C cultures), at 250

ng/ml for COL, 500 ng/ml for all other strains. 11S and furimazine were added at 220 minutes

(37°C cultures), 280 minutes (34°C cultures) or 310 minutes (30°C cultures). OD$_{600nm}$ and

luminescence readings were taken every 10 minutes.

Acknowledgements

This study was supported by the Wellcome Trust, through Investigator awards 10183/Z/15/Z

and 224151/Z/21/Z to TP, and the China Scholarship Council through award of a PhD

studentship to YY. We thank Ben Berks and Xiaolong Liu for advice and reagents for the

NanoLuc assay, Ian Collinson for plasmid pBAD-$_{6H}$11S for purification of 11S, José Penadés for

S. aureus strain JP5347, Simon Heilbronner for USA300 LAC and Sharon Peacock for strain

EMRSA-15.

Figure legends

Figure 1. The NanoLuc T7-secretion assay

A. Schematic representation of the NanoLuc assay. The T7 substrate EsxA with a C-terminal

pep86 tag is produced in the *S. aureus* cytoplasm, and 11S and furimazine (the NanoLuc large

subunit and substrate) are provided outside the cell. Secretion of EsxA-pep86 via the T7SS

results in functional complementation of 11S, which luminesces in the presence of furimazine

and O_2. Note that the cartoon is not an accurate representation of the stoichiometry and

architecture of the T7SSb, which are unknown. B., D. *S. aureus* strain COL or an isogenic Δ*essC*

mutant carrying the indicated plasmids were grown aerobically in 5 ml culture volumes. At

$OD_{600nm} = 0.5$, anhydrotetracycline (ATC) was added to induce expression from pRab11. When

cells reached $OD_{600nm} = 2$, samples corresponding to the culture medium ('supernatant') and

lysed cells ('cytoplasm') were prepared. Serial two-fold dilutions of unprocessed whole cell

cultures, supernatant and cytoplasmic fractions were subsequently supplemented with 11S

and furimazine. The data presented correspond to the mean luminescence readings of five

biological replicates and error bars represent the SEM. Two-way ANOVA was used to

determine statistical significance, **** $p < 0.0001$, ns - not significant. C., E. Lysed cell (wc)

and supernatant (sn) fractions from (B) and (D) were analysed by immunoblot with antibodies

against EsxA (top panles) or TrxA (bottom panels). Supernatant samples were concentrated

by TCA precipitation prior to analysis, and the amount analysed corresponds to 6 x more

culture volume than for lysed cell samples.

Figure 2. High throughput secretion analysis of chromosomally-encoded EsxA-pep86.

A. *S. aureus* COL, COL encoding chromosomal pep86-tagged EsxA (COL*esxA-pep86*) or COL Δ*essC*

encoding chromosomally pep86-tagged EsxA (COL*esxA-pep86* Δ*essC*) harbouring plasmid

pRab11-CBED-DEG (annotated as pEsaD-HA) were grown aerobically in 5 ml culture volumes

and ATC was added at $OD_{600nm} = 0.5$ to induce expression from pRab11. At $OD_{600nm} = 2$, lysed

whole cell (wc) and supernatant (sn) fractions were prepared and analysed by immunoblot

with antibodies against the HA tag (to detect EsaD-HA), EsxA or TrxA as indicated. Supernatant

samples were concentrated by TCA precipitation prior to analysis, and the amount analysed

corresponds to 6 x more culture volume than for lysed cell samples. B. Growth curves for

COL*esxA-pep86* and COL*esxA-pep86* Δ*essC*. 192 replicate 50 µl cultures (64 x 3 biological replicates)

for each strain were grown in 384-well plates at 37°C. Furimazine and 11S were added at 6h

(dotted line). Mean OD_{600nm} values were plotted and error bars correspond to the SEM (n=3).

C. Luminescence readings were recorded at ten minute intervals for each of the cultures in

(B) following addition of furimazine and 11S. D. A single overnight culture of each of COL_{esxA-}

$_{pep86}$ and $COL_{esxA-pep86}$ $\Delta essC$ was diluted to an OD_{600} of 0.1 and used to inoculate 64 individual

wells of a 384 well plate (Fig. 2B). The plate was cultures for 360 minutes after which

furimazine and 11S were added and a single luminescence reading from each well taken at

430 minutes. E. As part D except that three overnight cultures of each of $COL_{esxA-pep86}$ and

$COL_{esxA-pep86}$ $\Delta essC$ were used, giving 192 individual data points for each strain. Statistical

significance in D and E were assessed with the Mann-Whitney test, **** $p < 0.0001$.

Figure 3. Comparison of EsxA secretion in different* S. aureus *strains.

A. The six pairs of wild-type / $\Delta essC$ strains, as indicated, were transformed with pRab11-

EsxAp86 and cultured in 384-well plates at 37°C. Expression of *esxA-p86* was induced by

addition of ATC at 180 minutes, and luminescence was initiated by addition of furimazine and

11S at 220 minutes. Graphs show mean luminescence readings for each pair of strains taken

every ten minutes following initiation of luminescence. Data represent the mean of three

biological replicates with 64 cultures per replicate. Error bars correspond to the SEM (n=3). B.

Raw luminescence values from (A) were normalised for OD_{600nm}. Normalised values for each

$\Delta essC$ were subtracted from normalised values for the respective wild type to give a relative

secretion value for each time point. For each strain pair the time point showing the largest

luminescence difference between the wild type and $\Delta essC$ is presented.

Figure 4. Temperature dependence of EsxA secretion

A. Three pairs of wild-type / $\Delta essC$ strains, as indicated were transformed with pRab11-

EsxAp86 and cultured in 384-well plates at 30°C and 34°C. Expression of *esxA-pep86* was

induced by addition of ATC at the beginning of exponential phase (see Fig. S3), and

luminescence was initiated by addition of furimazine and 11S. Graphs show mean

luminescence readings for each pair of strains taken every ten minutes following initiation of

luminescence. B. Raw luminescence values from (A) were normalised for OD_{600nm}. Normalised

$\Delta essC$ values were subtracted from normalised WT values to give a relative secretion value

for each time point. For each strain pair the time point showing the largest luminescence

difference between the wild type and Δ*essC* is presented. Values for secretion at 37°C are

reproduced from Fig. 3B for comparison. In all cases, data represent the mean of three

biological replicates with 64 cultures per replicate. Error bars correspond to the SEM.

References

1. Turner NA, Sharma-Kuinkel BK, Maskarinec SA, Eichenberger EM, Shah PP, Carugati M, et al. Methicillin-resistant *Staphylococcus aureus*: an overview of basic and clinical research. Nat Rev Microbiol. 2019;17(4):203-18.

2. Shariati A, Dadashi M, Moghadam MT, van Belkum A, Yaslianifard S, Darban-Sarokhalil D. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate *Staphylococcus aureus* clinical isolates: a systematic review and meta-analysis. Sci Rep. 2020;10(1):12689.

3. Cao Z, Casabona MG, Kneuper H, Chalmers JD, Palmer T. The type VII secretion system of *Staphylococcus aureus* secretes a nuclease toxin that targets competitor bacteria. Nat Microbiol. 2016;2:16183.

4. Bowman L, Palmer T. The Type VII Secretion System of *Staphylococcus*. Annu Rev Microbiol. 2021;75:471-94.

5. Burts ML, DeDent AC, Missiakas DM. EsaC substrate for the ESAT-6 secretion pathway and its role in persistent infections of *Staphylococcus aureus*. Mol Microbiol. 2008;69(3):736-46.

6. Burts ML, Williams WA, DeBord K, Missiakas DM. EsxA and EsxB are secreted by an ESAT-6-like system that is required for the pathogenesis of *Staphylococcus aureus* infections. Proc Natl Acad Sci U S A. 2005;102(4):1169-74.

7. Kneuper H, Cao ZP, Twomey KB, Zoltner M, Jager F, Cargill JS, et al. Heterogeneity in *ess* transcriptional organization and variable contribution of the Ess/Type VII protein secretion system to virulence across closely related *Staphyloccus aureus* strains. Mol Microbiol. 2014;93(5):928-43.

8. Ishii K, Adachi T, Yasukawa J, Suzuki Y, Hamamoto H, Sekimizu K. Induction of Virulence Gene Expression in *Staphylococcus aureus* by Pulmonary Surfactant. Infect Immun. 2014;82(4):1500-10.

9. Wang Y, Hu M, Liu Q, Qin J, Dai Y, He L, et al. Role of the ESAT-6 secretion system in virulence of the emerging community-associated *Staphylococcus aureus* lineage ST398. Sci Rep. 2016;6:25163.

10. Whitney JC, Peterson SB, Kim J, Pazos M, Verster AJ, Radey MC, et al. A broadly distributed toxin family mediates contact-dependent antagonism between gram-positive bacteria. Elife. 2017;6.

11. Kobayashi K. Diverse LXG toxin and antitoxin systems specifically mediate intraspecies competition in *Bacillus subtilis* biofilms. PLoS Genet. 2021;17(7):e1009682.

12. Chatterjee A, Willett JLE, Dunny GM, Duerkop BA. Phage infection and sub-lethal antibiotic exposure mediate *Enterococcus faecalis* type VII secretion system dependent inhibition of bystander bacteria. PLoS Genet. 2021;17(1):e1009204.

13. Warne B, Harkins CP, Harris SR, Vatsiou A, Stanley-Wall N, Parkhill J, et al. The Ess/Type
VII secretion system of *Staphylococcus aureus* shows unexpected genetic diversity. BMC
Genomics. 2016;17(1):222.

14. Bunduc CM, Fahrenkamp D, Wald J, Ummels R, Bitter W, Houben ENG, et al. Structure and
dynamics of a mycobacterial type VII secretion system. Nature. 2021;593(7859):445-8.

15. Beckham KSH, Ritter C, Chojnowski G, Ziemianowicz DS, Mullapudi E, Rettel M, et al.
Structure of the mycobacterial ESX-5 type VII secretion system pore complex. Sci Adv.
2021;7(26).

16. Jager F, Kneuper H, Palmer T. EssC is a specificity determinant for *Staphylococcus aureus*
type VII secretion. Microbiology. 2018;164(5):816-20.

17. Huppert LA, Ramsdell TL, Chase MR, Sarracino DA, Fortune SM, Burton BM. The ESX
system in *Bacillus subtilis* mediates protein secretion. PLoS One. 2014;9(5):e96267.

18. Ulhuq FR, Gomes MC, Duggan GM, Guo M, Mendonca C, Buchanan G, et al. A membrane-
depolarizing toxin substrate of the *Staphylococcus aureus* type VII secretion system mediates
intraspecies competition. Proc Natl Acad Sci U S A. 2020;117(34):20836-47.

19. Anderson M, Aly KA, Chen YH, Missiakas D. Secretion of atypical protein substrates by the
ESAT-6 secretion system of *Staphylococcus aureus*. Mol Microbiol. 2013;90(4):734-43.

20. Casabona MG, Kneuper H, Alferes de Lima D, Harkins CP, Zoltner M, Hjerde E, et al. Haem-
iron plays a key role in the regulation of the Ess/type VII secretion system of *Staphylococcus*
aureus RN6390. Microbiology. 2017;163(12):1839-50.

21. Yang Y, Boardman E, Deme JC, Alcock F, Lea SM, Palmer T. EsxB, EsxC and EsxD facilitate
export of the antibacterial nuclease EsaD by the *Staphylococcus aureus* Type VII secretion
system. Biorxiv. 2023. doi: https://doi.org/10.1101/2023.04.01.535202

22. England CG, Ehlerding EB, Cai W. NanoLuc: A Small Luciferase Is Brightening Up the Field
of Bioluminescence. Bioconjug Chem. 2016;27(5):1175-87.

23. Allen WJ, Watkins DW, Dillingham MS, Collinson I. Refined measurement of SecA-driven
protein secretion reveals that translocation is indirectly coupled to ATP turnover. Proc Natl
Acad Sci U S A. 2020;117(50):31808-16.

24. Pereira GC, Allen WJ, Watkins DW, Buddrus L, Noone D, Liu X, et al. A High-Resolution
Luminescent Assay for Rapid and Continuous Monitoring of Protein Translocation across
Biological Membranes. J Mol Biol. 2019;431(8):1689-99.

25. Zhou W, Hao B, Bricker TM, Theg SM. A Real-Time Analysis of Protein Transport via the
Twin Arginine Translocation Pathway in Response to Different Components of the
Protonmotive Force in vivo. Biorxiv. 2023. doi: https://doi.org/10.1101/2023.01.12.523868

26. Spencer BL, Tak U, Mendonca JC, Nagao PE, Niederweis M, Doran KS. A type VII secretion
system in Group B *Streptococcus* mediates cytotoxicity and virulence. PLoS Pathog.
2021;17(12):e1010121.

27. Westerhausen S, Nowak M, Torres-Vargas CE, Bilitewski U, Bohn E, Grin I, et al. A NanoLuc
luciferase-based assay enabling the real-time analysis of protein secretion and injection by
bacterial type III secretion systems. Mol Microbiol. 2020;113(6):1240-54.

28. Schulthess B, Bloes DA, Berger-Bachi B. Opposing roles of sigmaB and sigmaB-controlled
SpoVG in the global regulation of *esxA* in *Staphylococcus aureus*. BMC Microbiol. 2012;12:17.

29. Crosby HA, Tiwari N, Kwiecinski JM, Xu Z, Dykstra A, Jenul C, et al. The *Staphylococcus
aureus* ArlRS two-component system regulates virulence factor expression through MgrA.
Mol Microbiol. 2020;113(1):103-22.

30. Dunman PM, Murphy E, Haney S, Palacios D, Tucker-Kellogg G, Wu S, et al. Transcription
profiling-based identification of *Staphylococcus aureus* genes regulated by the *agr* and/or
sarA loci. J Bacteriol. 2001;183(24):7341-53.

31. Monk IR, Shah IM, Xu M, Tan MW, Foster TJ. Transforming the untransformable:
application of direct transformation to manipulate genetically *Staphylococcus aureus* and
Staphylococcus epidermidis. mBio. 2012;3(2).

32. Monk IR, Stinear TP. From cloning to mutant in 5 days: rapid allelic exchange in
Staphylococcus aureus. Access Microbiol. 2021;3(2):000193.

Figure 1

Figure 2

Figure 3

Figure 4